Related Experiment Video

Updated: Sep 27, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.3K

Entry Inhibitors of Hepatitis B and D Viruses

Yang Yang1,2, Youhua Xie3,4

  • 1Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Institute of Infectious Diseases and Biosecurity, Shanghai Medical College, Fudan University, Shanghai, China.

Advances in Experimental Medicine and Biology
|April 12, 2022
PubMed

Insights

Hepatitis B and D viruses cause serious liver disease. Recent progress in understanding HBV entry has led to new inhibitors, including the first direct antiviral for HDV.

Area of Science:

  • Hepatology and Virology
  • Infectious Diseases
  • Drug Discovery

Background:

  • Hepatitis B virus (HBV) and hepatitis D virus (HDV) infections can lead to severe liver conditions like cirrhosis and liver cancer.
  • HBV and HDV primarily infect human hepatocytes, posing a significant public health challenge.
  • Understanding HBV's cell entry mechanism is crucial for developing new antiviral strategies.

Purpose of the Study:

  • To review recent advancements in HBV and HDV entry inhibitors.
  • To highlight the development of new HBV infection models.
  • To discuss the impact of entry inhibitor research on antiviral treatments.

Main Methods:

  • Literature review of recent studies on HBV/HDV entry mechanisms.
  • Analysis of research on viral entry inhibitors for HBV and HDV.
  • Examination of newly established HBV infection models.

Main Results:

  • Significant progress has been made in elucidating HBV cell entry pathways.
  • New HBV infection models have been established, facilitating research.
  • The development of HBV entry inhibitors has led to the first direct antiviral therapy for HDV.

Conclusions:

  • Understanding viral entry is key to developing effective hepatitis treatments.
  • Entry inhibitors represent a promising therapeutic avenue for HBV and HDV infections.
  • Recent breakthroughs offer new hope for managing chronic hepatitis and preventing liver disease progression.

Keywords:
Entry inhibitorsEnvelope proteinsHBVHost receptor

More Related Videos

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.4K
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

6.9K

Related Concept Videos

Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
178
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
80.1K